CN113009061A - 一种同时检测血液样品中多种胆汁酸的方法及试剂盒 - Google Patents
一种同时检测血液样品中多种胆汁酸的方法及试剂盒 Download PDFInfo
- Publication number
- CN113009061A CN113009061A CN202110231803.8A CN202110231803A CN113009061A CN 113009061 A CN113009061 A CN 113009061A CN 202110231803 A CN202110231803 A CN 202110231803A CN 113009061 A CN113009061 A CN 113009061A
- Authority
- CN
- China
- Prior art keywords
- acid
- bile acids
- sample
- taurocholic
- standard
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003613 bile acid Substances 0.000 title claims abstract description 56
- 238000000034 method Methods 0.000 title claims abstract description 30
- 210000004369 blood Anatomy 0.000 title claims abstract description 20
- 239000008280 blood Substances 0.000 title claims abstract description 20
- 238000001514 detection method Methods 0.000 claims abstract description 19
- 239000000126 substance Substances 0.000 claims abstract description 18
- 210000002966 serum Anatomy 0.000 claims abstract description 14
- 150000002500 ions Chemical class 0.000 claims abstract description 12
- 238000003908 quality control method Methods 0.000 claims abstract description 8
- 239000000047 product Substances 0.000 claims abstract description 7
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 claims abstract description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 42
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 claims description 34
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 claims description 34
- GHCZAUBVMUEKKP-UHFFFAOYSA-N ursodeoxycholic acid glycine-conjugate Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)CC2 GHCZAUBVMUEKKP-UHFFFAOYSA-N 0.000 claims description 32
- WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 claims description 29
- WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 claims description 29
- AWDRATDZQPNJFN-VAYUFCLWSA-N taurodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 AWDRATDZQPNJFN-VAYUFCLWSA-N 0.000 claims description 26
- BHTRKEVKTKCXOH-UHFFFAOYSA-N Taurochenodesoxycholsaeure Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)CC2 BHTRKEVKTKCXOH-UHFFFAOYSA-N 0.000 claims description 25
- 239000012086 standard solution Substances 0.000 claims description 23
- 108010035713 Glycodeoxycholic Acid Proteins 0.000 claims description 18
- WVULKSPCQVQLCU-UHFFFAOYSA-N Glycodeoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 WVULKSPCQVQLCU-UHFFFAOYSA-N 0.000 claims description 18
- WVULKSPCQVQLCU-BUXLTGKBSA-N glycodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 WVULKSPCQVQLCU-BUXLTGKBSA-N 0.000 claims description 18
- BHTRKEVKTKCXOH-LBSADWJPSA-N tauroursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)CC1 BHTRKEVKTKCXOH-LBSADWJPSA-N 0.000 claims description 18
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 claims description 17
- 239000004380 Cholic acid Substances 0.000 claims description 17
- 108010015031 Glycochenodeoxycholic Acid Proteins 0.000 claims description 17
- 108010007979 Glycocholic Acid Proteins 0.000 claims description 17
- DGABKXLVXPYZII-UHFFFAOYSA-N Hyodeoxycholic acid Natural products C1C(O)C2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 DGABKXLVXPYZII-UHFFFAOYSA-N 0.000 claims description 17
- SMEROWZSTRWXGI-UHFFFAOYSA-N Lithocholsaeure Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 SMEROWZSTRWXGI-UHFFFAOYSA-N 0.000 claims description 17
- RFDAIACWWDREDC-UHFFFAOYSA-N Na salt-Glycocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 RFDAIACWWDREDC-UHFFFAOYSA-N 0.000 claims description 17
- 229960001091 chenodeoxycholic acid Drugs 0.000 claims description 17
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 claims description 17
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 claims description 17
- 229960002471 cholic acid Drugs 0.000 claims description 17
- 235000019416 cholic acid Nutrition 0.000 claims description 17
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims description 17
- 229960003964 deoxycholic acid Drugs 0.000 claims description 17
- GHCZAUBVMUEKKP-GYPHWSFCSA-N glycochenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)CC1 GHCZAUBVMUEKKP-GYPHWSFCSA-N 0.000 claims description 17
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 claims description 17
- 229940099347 glycocholic acid Drugs 0.000 claims description 17
- DGABKXLVXPYZII-SIBKNCMHSA-N hyodeoxycholic acid Chemical compound C([C@H]1[C@@H](O)C2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 DGABKXLVXPYZII-SIBKNCMHSA-N 0.000 claims description 17
- SMEROWZSTRWXGI-HVATVPOCSA-N lithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 SMEROWZSTRWXGI-HVATVPOCSA-N 0.000 claims description 17
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 claims description 17
- 229960001661 ursodiol Drugs 0.000 claims description 17
- GHCZAUBVMUEKKP-NHIHLBCISA-N 2-[[(4R)-4-[(3R,5S,7S,10S,13R,17R)-3,7-Dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]acetic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)C1C2C2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)CC1 GHCZAUBVMUEKKP-NHIHLBCISA-N 0.000 claims description 15
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 15
- 239000011550 stock solution Substances 0.000 claims description 10
- 239000000243 solution Substances 0.000 claims description 8
- 238000010828 elution Methods 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- BHTRKEVKTKCXOH-AYSJQVDDSA-N taurochenodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)C1C2C2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)CC1 BHTRKEVKTKCXOH-AYSJQVDDSA-N 0.000 claims description 7
- 238000010438 heat treatment Methods 0.000 claims description 6
- 239000012528 membrane Substances 0.000 claims description 6
- 239000012452 mother liquor Substances 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 6
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 claims description 5
- 239000005695 Ammonium acetate Substances 0.000 claims description 5
- 229940043376 ammonium acetate Drugs 0.000 claims description 5
- 235000019257 ammonium acetate Nutrition 0.000 claims description 5
- 238000007865 diluting Methods 0.000 claims description 5
- 238000001819 mass spectrum Methods 0.000 claims description 5
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 3
- 229910052782 aluminium Inorganic materials 0.000 claims description 3
- 238000010790 dilution Methods 0.000 claims description 3
- 239000012895 dilution Substances 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 239000011888 foil Substances 0.000 claims description 3
- 238000007789 sealing Methods 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 238000003260 vortexing Methods 0.000 claims description 3
- 239000003643 water by type Substances 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 abstract description 13
- 239000002253 acid Substances 0.000 abstract description 6
- 238000011002 quantification Methods 0.000 abstract description 3
- 238000005516 engineering process Methods 0.000 abstract description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 abstract description 2
- 238000007689 inspection Methods 0.000 abstract description 2
- 230000014759 maintenance of location Effects 0.000 abstract description 2
- 238000013375 chromatographic separation Methods 0.000 abstract 1
- 239000013589 supplement Substances 0.000 abstract 1
- 230000004907 flux Effects 0.000 description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 3
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 3
- JXTHEWSKYLZVJC-UHFFFAOYSA-N naptalam Chemical compound OC(=O)C1=CC=CC=C1C(=O)NC1=CC=CC2=CC=CC=C12 JXTHEWSKYLZVJC-UHFFFAOYSA-N 0.000 description 3
- QBYUNVOYXHFVKC-GBURMNQMSA-N taurolithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)CC1 QBYUNVOYXHFVKC-GBURMNQMSA-N 0.000 description 3
- 238000012417 linear regression Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- KIFLPMXYKUVOII-SFHVURJKSA-N C1(=CC=CC2=CC=CC=C12)N[C@@H](CC1=CC=CC=C1)C(=O)O Chemical compound C1(=CC=CC2=CC=CC=C12)N[C@@H](CC1=CC=CC=C1)C(=O)O KIFLPMXYKUVOII-SFHVURJKSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
- G01N30/14—Preparation by elimination of some components
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N2030/022—Column chromatography characterised by the kind of separation mechanism
- G01N2030/027—Liquid chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
- G01N30/14—Preparation by elimination of some components
- G01N2030/146—Preparation by elimination of some components using membranes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
- G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
- G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
- G01N2030/8822—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving blood
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Steroid Compounds (AREA)
Abstract
本发明公开了一种同时检测血液样品中多种胆汁酸的方法及试剂盒,属于胆汁酸检测技术领域。本发明公开的一种同时检测血液样品中多种胆汁酸的方法,先对样本进行前处理,再进入色谱分离及质谱检测,针对每种胆汁酸分别选择一对定性离子和一对定量离子,以各种胆汁酸的相对保留时间和定性离子对作为定性依据,以标准品制作标准曲线定量。同时,本发明方法应用三个水平的质控品考察方法的准确性、有效性,避免检测结果失真。本发明首次实现了应用LC‑MS技术对一份血清样本中的十五种胆汁酸同时检测的目的,减小了干扰物影响,该方法操作简便快速,有效监测人体内胆汁酸水平,对胆汁酸的合理、安全补充具有指导意义,易于临床推广及普及。
Description
技术领域
本发明涉及胆汁酸检测技术领域,更具体的说是涉及一种同时检测血液样品中多种胆汁酸的方法及试剂盒。
背景技术
胆汁酸由胆固醇代谢产生,根据合成途径,可以分为由胆固醇为原料直接合成的初级胆汁酸和代谢产生的次级胆汁酸。胆汁酸是胆汁的重要组成成分,是人体脂肪代谢的必须物质。胆汁酸不仅能够调节葡萄糖和脂肪代谢,还能与肠道菌群相互作用,具有重要的临床意义。现有检测方法只能简单地定量测量总胆汁酸水平,不能定量检测每一种亚型的胆汁酸在体内的水平。
现有技术中,常用的胆汁酸检测方法主要包括气相色谱法、液相色谱法、毛细管电泳法、气相色谱-质谱联用法,以及液相色谱-串联质谱法等。但是目前对于检测人体血清中胆汁酸亚型的研究相对较少,方法通量较低,也缺乏健康人参考范围。
因此,提供一种同时检测血液样品中多种胆汁酸的方法及试剂盒是本领域技术人员亟需解决的问题。
发明内容
有鉴于此,本发明提供了一种同时检测血液样品中多种胆汁酸的方法及试剂盒。
为了实现上述目的,本发明采用如下技术方案:
一种同时检测血液样品中多种胆汁酸的方法,采用LC-MS检测血液样品中多种胆汁酸;色谱条件:色谱柱:Waters ACQUITYUPLC HSS T3,1.8μm,2.1×100mm,柱温:30℃;流动相A:5mM乙酸铵溶液,流动相B:乙腈;梯度洗脱条件:0-1.2min 30-35%B,1.2-2min 35%B,2-3min 35-41%B,3-4min 41-45%B,4-4.5min 45%B,4.5-5.3min 45%B,5.3-5.5min45-80%B,5.5-7.5min 80%B,7.5-8.7min 80-35%B,8.7-9.2min 35%B,9.2-10.5min35%B,流速0.4mL/min,进样量1μL;质谱条件:采用ESI源,MRM正负离子扫描模式,雾化气流量为3L/min,加热气流量为13L/min,接口温度为350℃,DL温度为250℃,加热块温度为400℃,干燥气流量为7L/min。
梯度洗脱条件:
MRM质谱参数如下:
进一步,所述血液样品为血浆或血清。
进一步,所述多种胆汁酸为牛磺熊去氧胆酸、牛磺脱氧胆酸、猪去氧胆酸、鹅去氧胆酸、甘氨鹅去氧胆酸、牛磺鹅去氧胆酸、熊去氧胆酸、去氧胆酸、甘氨脱氧胆酸、甘氨熊去氧胆酸、甘氨胆酸、胆酸、石胆酸、牛磺胆酸和牛磺石胆酸中的至少两种。
优选地,所述多种胆汁酸为牛磺熊去氧胆酸、牛磺脱氧胆酸、猪去氧胆酸、鹅去氧胆酸、甘氨鹅去氧胆酸、牛磺鹅去氧胆酸、熊去氧胆酸、去氧胆酸、甘氨脱氧胆酸、甘氨熊去氧胆酸、甘氨胆酸、胆酸、石胆酸、牛磺胆酸和牛磺石胆酸。
进一步,一种同时检测血液样品中多种胆汁酸的方法,具体步骤如下:
(1)待测样本处理:取样本涡旋30s后,取400μl悬浮液样本于1.5ml Ep管中,4℃以13000rpm离心15min;取上清液100μL,置于1.5mL Ep管,加入100μL甲醇稀释;加入1μL N-1-萘基酞氨酸内标溶液混匀后用0.22μm微孔滤膜过滤,将全部样品转移至96孔板中,覆上铝箔封膜,检测备用;
(2)标准溶液配制:标准品(牛磺熊去氧胆酸、牛磺脱氧胆酸、猪去氧胆酸、鹅去氧胆酸、甘氨鹅去氧胆酸、牛磺鹅去氧胆酸、熊去氧胆酸、去氧胆酸、甘氨脱氧胆酸、甘氨熊去氧胆酸、甘氨胆酸、胆酸、石胆酸、牛磺胆酸和牛磺石胆酸)均用甲醇溶解,配制成单标母液浓度为5mM的标准品,分别取各单标母液等量混合成浓度为0.33mM的混合储备液,用甲醇稀释系列浓度;
(3)内标溶液配制:内标用甲醇稀释,配制成浓度为0.033mM的内标储备液;
(4)LC-MS检测:将待测样本通过梯度洗脱模式进入色谱柱分离后,对待测物质进行定性与定量检测。
进一步,一种同时检测血液样品中多种胆汁酸的试剂盒,包括如下组分:标准溶液,内标溶液,甲醇,乙腈,5mM乙酸铵溶液,质控品;所述多种胆汁酸为牛磺熊去氧胆酸、牛磺脱氧胆酸、猪去氧胆酸、鹅去氧胆酸、甘氨鹅去氧胆酸、牛磺鹅去氧胆酸、熊去氧胆酸、去氧胆酸、甘氨脱氧胆酸、甘氨熊去氧胆酸、甘氨胆酸、胆酸、石胆酸、牛磺胆酸和牛磺石胆酸中的至少两种。
进一步,标准溶液为由标准品(牛磺熊去氧胆酸、牛磺脱氧胆酸、猪去氧胆酸、鹅去氧胆酸、甘氨鹅去氧胆酸、牛磺鹅去氧胆酸、熊去氧胆酸、去氧胆酸、甘氨脱氧胆酸、甘氨熊去氧胆酸、甘氨胆酸、胆酸、石胆酸、牛磺胆酸和牛磺石胆酸中的至少两种)等量混合成的浓度为0.33mM的混合储备液。
进一步,内标溶液为浓度0.033mM的N-1-萘基酞氨酸溶液。
进一步,所述的试剂盒在同时检测牛磺熊去氧胆酸、牛磺脱氧胆酸、猪去氧胆酸、鹅去氧胆酸、甘氨鹅去氧胆酸、牛磺鹅去氧胆酸、熊去氧胆酸、去氧胆酸、甘氨脱氧胆酸、甘氨熊去氧胆酸、甘氨胆酸、胆酸、石胆酸、牛磺胆酸和牛磺石胆酸中的应用。
质控品:含有三个水平的低、中、高浓度质控血清,质控品由人工血清添加混合胆汁酸标准物质制得,并通过检测确定靶值。
应用标准品制作标准曲线,以标准溶液浓度为X轴,标准品峰面积为Y轴;进行线性回归分析得回归方程。将相应胆汁酸峰面积代入标准曲线方程,分别计算血清样品中十五种胆汁酸的浓度。
经由上述的技术方案可知,与现有技术相比,本发明公开提供了一种同时检测血液样品中多种胆汁酸的方法及试剂盒,对样本前处理方法和超高效液相色谱-质谱条件进行了优化;进而提供一种同时测定血清中牛磺熊去氧胆酸、牛磺脱氧胆酸、猪去氧胆酸、鹅去氧胆酸、甘氨鹅去氧胆酸、牛磺鹅去氧胆酸、熊去氧胆酸、去氧胆酸、甘氨脱氧胆酸、甘氨熊去氧胆酸、甘氨胆酸、胆酸、石胆酸、牛磺胆酸和牛磺石胆酸的方法。
采用本发明可以同时检测人血清中十五种胆汁酸牛磺熊去氧胆酸、牛磺脱氧胆酸、猪去氧胆酸、鹅去氧胆酸、甘氨鹅去氧胆酸、牛磺鹅去氧胆酸、熊去氧胆酸、去氧胆酸、甘氨脱氧胆酸、甘氨熊去氧胆酸、甘氨胆酸、胆酸、石胆酸、牛磺胆酸和牛磺石胆酸的含量,并进行精确的定性和定量分析,是一种样本处理简单、通量高、结果可靠的检测方法。
本发明使用的样本处理方法,可以较多地去除杂质,降低检测时的基质效应,且操作简单快捷,可以灵敏地检测出各种胆汁酸的含量。
本发明可以同时检测十五种胆汁酸,一是降低了检测成本,二是节省时间,三是减少采集被检测人的血量,四是可以对多种胆汁酸的补充提供依据。
本发明用超高效液相色谱-质谱法检测血清中十五种胆汁酸,特异性强,灵敏性高,通量高,结果客观易于分析,尤其适合临床普及应用。基于该方法的试剂盒对于肝胆和肠道疾病的筛查、诊断和鉴别诊断具有重要意义。
本发明方法针对每种胆汁酸分别选择一对定性离子和一对定量离子,以各种胆汁酸的相对保留时间和定性离子对作为定性依据,以标准品制作标准曲线定量。同时,本发明方法应用三个水平的质控品考察方法的准确性、有效性,避免检测结果失真。
本发明首次实现了应用LC-MS技术对一份血清样本中的十五种胆汁酸同时检测的目的,用两对离子分别进行定量和定性保证了检测物的特异性,降低了干扰物影响;该方法操作简便快速,分析时间仅10.5min,通量高、成本低,能有效监测人体内胆汁酸水平。
附图说明
为了更清楚地说明本发明实施例或现有技术中的技术方案,下面将对实施例或现有技术描述中所需要使用的附图作简单地介绍,显而易见地,下面描述中的附图仅仅是本发明的实施例,对于本领域普通技术人员来讲,在不付出创造性劳动的前提下,还可以根据提供的附图获得其他的附图。
图1附图为本发明实施例1的十五种胆汁酸总离子流谱图;
图2附图为本发明实施例1的牛磺熊去氧胆酸标准品的色谱图;
图3附图为本发明实施例1的牛磺脱氧胆酸标准品(在4.2min出峰)的色谱图;
图4附图为本发明实施例1的猪去氧胆酸标准品(在2.78min出峰)的色谱图;
图5附图为本发明实施例1的鹅去氧胆酸标准品(在5.2min出峰)的色谱图;
图6附图为本发明实施例1的甘氨鹅去氧胆酸标准品(在2.9min出峰)的色谱图;
图7附图为本发明实施例1的牛磺鹅去氧胆酸标准品(在3.6min出峰)的色谱图;
图8附图为本发明实施例1的熊去氧胆酸标准品(在2.6min出峰)的色谱图;
图9附图为本发明实施例1的去氧胆酸标准品的色谱图;
图10附图为本发明实施例1的甘氨脱氧胆酸标准品(在3.59min出峰)的色谱图;
图11附图为本发明实施例1的甘氨熊去氧胆酸标准品的色谱图;
图12附图为本发明实施例1的甘氨胆酸标准品的色谱图;
图13附图为本发明实施例1的胆酸标准品的色谱图;
图14附图为本发明实施例1的石胆酸标准品的色谱图;
图15附图为本发明实施例1的牛磺胆酸标准品的色谱图;
图16附图为本发明实施例1的牛磺石胆酸标准品的色谱图;
图17附图为本发明实施例1的N-1-萘基酞氨酸内标(在0.87min出峰)的色谱图。
具体实施方式
下面将结合本发明实施例中的附图,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
牛磺熊去氧胆酸、牛磺脱氧胆酸、猪去氧胆酸、鹅去氧胆酸、甘氨鹅去氧胆酸、牛磺鹅去氧胆酸、熊去氧胆酸、去氧胆酸、甘氨脱氧胆酸、甘氨熊去氧胆酸、甘氨胆酸、胆酸、石胆酸、牛磺胆酸和牛磺石胆酸标准品购自Sigma-Aldrich;N-1-萘基酞氨酸内标来自剑桥同位素实验室。
实施例1
一种同时检测血液样品中多种胆汁酸的方法,步骤如下:
(1)制备待测样本
取样本涡旋30s后,取400μl悬浮液样本于1.5ml Ep管中,4℃以13000rpm离心15min;取上清液100μL,置于1.5mL Ep管,加入100μL甲醇稀释;加入1μL N-1-萘基酞氨酸内标溶液(0.033mM)混匀后用0.22μm微孔滤膜过滤,将全部样品转移至96孔板中,覆上铝箔封膜,检测备用;
(2)超高效液相色谱-质谱检测
待测样本通过梯度洗脱模式进入色谱柱分离,液相色谱参考条件:
色谱柱:Waters ACQUITYUPLC HSS T3(1.8μm,2.1×100mm)
柱温:30℃
进样体积:1μL
流速:0.4ml/min
流动相A:5mM乙酸铵溶液
流动相B:乙腈
梯度洗脱条件:
质谱参数参考条件:
ESI源,MRM正负离子扫描模式
雾化气流量:3L/min
加热气流量:13L/min
接口温度:350℃
加热块温度:400℃
DL温度:250℃
干燥气流量:7L/min
MRM质谱参数如下:
十五种胆汁酸总离子流谱图见图1;牛磺熊去氧胆酸、牛磺脱氧胆酸、猪去氧胆酸、鹅去氧胆酸、甘氨鹅去氧胆酸、牛磺鹅去氧胆酸、熊去氧胆酸、去氧胆酸、甘氨脱氧胆酸、甘氨熊去氧胆酸、甘氨胆酸、胆酸、石胆酸、牛磺胆酸、牛磺石胆酸标准品的色谱图见图2-16;N-1-萘基酞氨酸内标的色谱图见图17。其中,色谱图的横坐标为时间,单位min;纵坐标为响应值。
(3)计算结果
标准溶液的配制:标准品(牛磺熊去氧胆酸、牛磺脱氧胆酸、猪去氧胆酸、鹅去氧胆酸、甘氨鹅去氧胆酸、牛磺鹅去氧胆酸、熊去氧胆酸、去氧胆酸、甘氨脱氧胆酸、甘氨熊去氧胆酸、甘氨胆酸、胆酸、石胆酸、牛磺胆酸和牛磺石胆酸)均用甲醇溶解,配制成单标母液浓度为5mM的标准品,分别取各单标母液等量混合成浓度约为0.33mM的混合储备液,用甲醇稀释系列浓度,-20℃保存备用;
内标溶液的配制:N-1-萘基酞氨酸内标用甲醇稀释,配制成浓度约为0.033mM的内标储备液,-20℃保存备用。
应用标准品制作标准曲线,以标准溶液浓度为X轴,标准品峰面积为Y轴;进行线性回归分析得回归方程。将相应胆汁酸峰面积代入标准曲线方程,分别计算血清样品中十五种胆汁酸的浓度。各个胆汁酸的线性范围、线性相关系数、检出限及回归方程如下表所示:
提取回收率和精密度试验:向血清中分别添加低、中、高3种浓度的标准溶液,其中鹅去氧胆酸、熊去氧胆酸、去氧胆酸、胆酸、石胆酸的3个加标准溶液水平分别为3.0、1000.0、1500nmol/L;牛磺鹅去氧胆酸、甘氨脱氧胆酸、甘氨胆酸、牛磺胆酸的3个加标准溶液水平分别为30.0、3000.0、4500nmol/L;牛磺熊去氧胆酸、牛磺脱氧胆酸、猪去氧胆酸、甘氨鹅去氧胆酸、甘氨熊去氧胆酸、牛磺石胆酸的3个加标准溶液水平分别为30.0、1000.0、1500nmol/L。按照“制备待测样本”项处理标本,每个添加浓度平行测定6次。根据样品结果计算本法的回收率和精密度。
由下表可知,15种胆汁酸精密度的RSD值在0-15%之间,表明精密度良好。回收率在85-115%之间,回收率较高,说明本发明方法的准确度良好。
实验证明,本发明样本处理简单,通量高,成本低,可以同时检测人体内十五种胆汁酸,具有非常重要的意义。
对所公开的实施例的上述说明,使本领域专业技术人员能够实现或使用本发明。对这些实施例的多种修改对本领域的专业技术人员来说将是显而易见的,本文中所定义的一般原理可以在不脱离本发明的精神或范围的情况下,在其它实施例中实现。因此,本发明将不会被限制于本文所示的这些实施例,而是要符合与本文所公开的原理和新颖特点相一致的最宽的范围。
Claims (7)
1.一种同时检测血液样品中多种胆汁酸的方法,其特征在于,采用LC-MS检测血液样品中多种胆汁酸;色谱条件:色谱柱:Waters ACQUITYUPLC HSS T3,1.8μm,2.1×100mm,柱温:30℃;流动相A:5mM乙酸铵溶液,流动相B:乙腈;梯度洗脱条件:0-1.2min 30-35%B,1.2-2min 35%B,2-3min35-41%B,3-4min 41-45%B,4-4.5min 45%B,4.5-5.3min 45%B,5.3-5.5min45-80%B,5.5-7.5min 80%B,7.5-8.7min 80-35%B,8.7-9.2min 35%B,9.2-10.5min 35%B,流速0.4mL/min,进样量1μL;质谱条件:采用ESI源,MRM正负离子扫描模式,雾化气流量为3L/min,加热气流量为13L/min,接口温度为350℃,DL温度为250℃,加热块温度为400℃,干燥气流量为7L/min。
2.根据权利要求1所述的一种同时检测血液样品中多种胆汁酸的方法,其特征在于,所述血液样品为血浆或血清。
3.根据权利要求1所述的一种同时检测血液样品中多种胆汁酸的方法,其特征在于,所述多种胆汁酸为牛磺熊去氧胆酸、牛磺脱氧胆酸、猪去氧胆酸、鹅去氧胆酸、甘氨鹅去氧胆酸、牛磺鹅去氧胆酸、熊去氧胆酸、去氧胆酸、甘氨脱氧胆酸、甘氨熊去氧胆酸、甘氨胆酸、胆酸、石胆酸、牛磺胆酸和牛磺石胆酸中的至少两种。
4.根据权利要求1所述的一种同时检测血液样品中多种胆汁酸的方法,其特征在于,所述多种胆汁酸为牛磺熊去氧胆酸、牛磺脱氧胆酸、猪去氧胆酸、鹅去氧胆酸、甘氨鹅去氧胆酸、牛磺鹅去氧胆酸、熊去氧胆酸、去氧胆酸、甘氨脱氧胆酸、甘氨熊去氧胆酸、甘氨胆酸、胆酸、石胆酸、牛磺胆酸和牛磺石胆酸。
5.根据权利要求1所述的一种同时检测血液样品中多种胆汁酸的方法,其特征在于,具体步骤如下:
(1)待测样本处理:取样本涡旋30s后,取400μl悬浮液样本于1.5ml Ep管中,4℃以13000rpm离心15min;取上清液100μL,置于1.5mL Ep管,加入100μL甲醇稀释;加入1μL N-1-萘基酞氨酸内标溶液混匀后用0.22μm微孔滤膜过滤,将全部样品转移至96孔板中,覆上铝箔封膜,检测备用;
(2)标准溶液配制:标准品均用甲醇溶解,配制成单标母液浓度为5mM的标准品,分别取各单标母液等量混合成浓度为0.33mM的混合储备液,用甲醇稀释系列浓度;
(3)内标溶液配制:内标用甲醇稀释,配制成浓度为0.033mM的内标储备液;
(4)LC-MS检测:将待测样本通过梯度洗脱模式进入色谱柱分离后,对待测物质进行定性与定量检测。
6.一种同时检测血液样品中多种胆汁酸的试剂盒,其特征在于,包括如下组分:标准溶液,内标溶液,甲醇,乙腈,5mM乙酸铵溶液,质控品;所述多种胆汁酸为牛磺熊去氧胆酸、牛磺脱氧胆酸、猪去氧胆酸、鹅去氧胆酸、甘氨鹅去氧胆酸、牛磺鹅去氧胆酸、熊去氧胆酸、去氧胆酸、甘氨脱氧胆酸、甘氨熊去氧胆酸、甘氨胆酸、胆酸、石胆酸、牛磺胆酸和牛磺石胆酸中的至少两种。
7.权利要求6所述的试剂盒在同时检测牛磺熊去氧胆酸、牛磺脱氧胆酸、猪去氧胆酸、鹅去氧胆酸、甘氨鹅去氧胆酸、牛磺鹅去氧胆酸、熊去氧胆酸、去氧胆酸、甘氨脱氧胆酸、甘氨熊去氧胆酸、甘氨胆酸、胆酸、石胆酸、牛磺胆酸和牛磺石胆酸中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110231803.8A CN113009061A (zh) | 2021-03-02 | 2021-03-02 | 一种同时检测血液样品中多种胆汁酸的方法及试剂盒 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110231803.8A CN113009061A (zh) | 2021-03-02 | 2021-03-02 | 一种同时检测血液样品中多种胆汁酸的方法及试剂盒 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113009061A true CN113009061A (zh) | 2021-06-22 |
Family
ID=76402758
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110231803.8A Pending CN113009061A (zh) | 2021-03-02 | 2021-03-02 | 一种同时检测血液样品中多种胆汁酸的方法及试剂盒 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113009061A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113960221A (zh) * | 2021-12-23 | 2022-01-21 | 中国中医科学院医学实验中心 | 基于粪便样本的胆汁酸全通路代谢轮廓的检测方法及其应用 |
CN115469035A (zh) * | 2022-09-27 | 2022-12-13 | 湖南泰新医药科技有限公司 | 测定人血浆中熊去氧胆酸及其代谢物浓度的方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101995441A (zh) * | 2010-02-10 | 2011-03-30 | 中国科学院大连化学物理研究所 | 检测血中3-硫酸甘氨鹅脱氧胆酸和甘氨鹅脱氧胆酸的试剂盒 |
CN102798672A (zh) * | 2011-05-21 | 2012-11-28 | 中国科学院大连化学物理研究所 | 一种检测血中gcdcs和gcdca的试剂盒 |
CN109030676A (zh) * | 2018-07-06 | 2018-12-18 | 易达精准(杭州)科技有限公司 | 同时测定16种胆汁酸的串联质谱检测试剂盒及其应用 |
-
2021
- 2021-03-02 CN CN202110231803.8A patent/CN113009061A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101995441A (zh) * | 2010-02-10 | 2011-03-30 | 中国科学院大连化学物理研究所 | 检测血中3-硫酸甘氨鹅脱氧胆酸和甘氨鹅脱氧胆酸的试剂盒 |
CN102798672A (zh) * | 2011-05-21 | 2012-11-28 | 中国科学院大连化学物理研究所 | 一种检测血中gcdcs和gcdca的试剂盒 |
CN109030676A (zh) * | 2018-07-06 | 2018-12-18 | 易达精准(杭州)科技有限公司 | 同时测定16种胆汁酸的串联质谱检测试剂盒及其应用 |
Non-Patent Citations (4)
Title |
---|
TANNAZ GHAFFARZADEGAN 等: "Determination of free and conjugated bile acids in serum of Apoe(−/−) mice fed different lingonberry fractions by UHPLC-MS", 《SCIENTIFIC REPORTS》 * |
XIAOFEN ZHANG 等: "Analysis of bile acid profile in plasma to differentiate cholangiocarcinoma from benign biliary diseases and healthy controls", 《THE JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY》 * |
YAO SHI 等: "Definitive profiling of plasma bile acids as potential biomarkers for human liver diseases using UPLC–HRMS", 《BIOANALYSIS》 * |
姚婷 等: "大菱鲆胆汁和血浆中的胆汁酸轮廓分析", 《动物营养学报》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113960221A (zh) * | 2021-12-23 | 2022-01-21 | 中国中医科学院医学实验中心 | 基于粪便样本的胆汁酸全通路代谢轮廓的检测方法及其应用 |
CN113960221B (zh) * | 2021-12-23 | 2022-02-25 | 中国中医科学院医学实验中心 | 基于粪便样本的胆汁酸全通路代谢轮廓的检测方法及其应用 |
CN115469035A (zh) * | 2022-09-27 | 2022-12-13 | 湖南泰新医药科技有限公司 | 测定人血浆中熊去氧胆酸及其代谢物浓度的方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ye et al. | High-performance liquid chromatography–tandem mass spectrometry for the analysis of bile acid profiles in serum of women with intrahepatic cholestasis of pregnancy | |
JP6082328B2 (ja) | 胆汁酸同時分析方法 | |
CN111175419B (zh) | 一种同时检测血液样品中多种类固醇激素的方法及试剂盒 | |
CN113009061A (zh) | 一种同时检测血液样品中多种胆汁酸的方法及试剂盒 | |
CN111307993B (zh) | 检测血液中胆汁酸含量的方法 | |
CN107843671A (zh) | 一种高通量液相色谱串联质谱的高通量液相色谱串联质谱的检测方法 | |
CN111257476A (zh) | 一种高效液相色谱串联质谱检测血清中17种胆汁酸的方法 | |
CN111474288A (zh) | 一种用于准确测定血清中胆汁酸浓度的质谱试剂盒 | |
CN111521705B (zh) | 一种血清中胆汁酸的富集方法 | |
CN107621502A (zh) | 基于lc‑ms/ms的胆汁和血清中16种胆汁酸的定量 | |
CN111323507A (zh) | 基于固相萃取法同时检测血清中11种类固醇的检测方法 | |
CN111595956B (zh) | 一种血清中激素和神经递质的检测方法 | |
CN111665308A (zh) | 一种检测血清中15种胆汁酸的试剂盒及其应用 | |
CN110596295A (zh) | 一种检测胆汁酸的方法 | |
CN109060983A (zh) | 一种液相色谱-串联质谱检测甲氧基肾上腺素类物质的方法 | |
CN112666291A (zh) | 基于高通量液相色谱-质谱联用技术的胆汁酸检测方法 | |
CN111912921A (zh) | 一种超高效液相色谱串联质谱技术检测血浆中3种脂质的方法 | |
CN106841492A (zh) | 高效液相色谱串联质谱检测血清中五种游离型胆汁酸的方法 | |
CN110794072A (zh) | 人血清中雌酮和雌二醇液相色谱串联质谱检测方法 | |
CN116519850B (zh) | 一种快速检测血清样本中16种激素浓度的方法 | |
CN109828043A (zh) | 一种人血浆中阿考替胺的定量分析方法 | |
CN113009036A (zh) | 一种检测性激素的试剂盒、性激素样品前处理方法及同时检测多种性激素的方法 | |
CN117368347A (zh) | 一种同时测定血浆中原发性醛固酮增多症分型标志物的液相色谱-串联质谱法 | |
CN111896646A (zh) | 一种超高效液相色谱串联质谱技术检测血浆中3种脂质的试剂盒 | |
CN111638287A (zh) | 一种检测人体干尿滤纸片中多种有机酸的定量检测方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Zhang Zhao Inventor after: Tian Tian Inventor after: Diao Jiayin Inventor after: Zheng Kangdi Inventor after: Chen Tao Inventor before: Zhang Zhao Inventor before: Diao Jiayin Inventor before: Zheng Kangdi Inventor before: Chen Tao |
|
CB03 | Change of inventor or designer information | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210622 |
|
RJ01 | Rejection of invention patent application after publication |